The decline of the pharmaceutical industry in Europe is becoming a big problem as the region faces a lot of pressure from the US and China. For a long time, Europe was where drug companies from all over the world wanted to go. But now that the European pharmaceutical industry is in trouble, companies are having to rethink where they put their money and how they make new drugs.
The pharmaceutical industry is an important part of Europe’s economy. But the decline of the European pharmaceutical industry isn’t just about money; it also hurts patients. Companies are staying away from the European market because of strict rules and lower prices, which is making it harder for people to get new medicines and launch drugs more slowly.
US Policies Speed Up the Decline of the European Pharma Industry
President Donald Trump’s harsh trade and pricing policies are one of the main reasons why the European pharmaceutical industry is going down. These rules are changing the way drug companies do business around the world.
The “most-favored-nation” pricing rule is one of the most important policies. This means that drug prices in the US will be the same as the lowest prices in other countries. Because of this, companies are now careful about releasing cheaper drugs in Europe, since it could hurt their profits in the U.S. Stadig made the situation very clear:
“has given drug companies a lever to pull the negotiations with European governments or European regulators,” he said.
Inside Story of Why US Iran Negotiations Fail
New U.S. tariffs of up to 100% on branded drugs have also made things worse. These tariffs may not hurt all businesses, but they do make the European pharmaceutical industry weaker by making companies focus more on the US market.
Drug companies still want to do business in the U.S. because prices are much higher there. The RAND Corporation did a study and found that drug prices in the U.S. are almost three times higher than in other developed countries. This makes the U.S. more profitable and speeds up the decline of the European pharmaceutical industry.
The rise of biotech in China makes the decline of the European pharmaceutical industry worse.
At the same time, China is quickly becoming a world leader in biotechnology. This is another big reason why the European pharmaceutical industry is going down.
China is now drawing in pharmaceutical companies from around the world because of its strong research and innovation skills. A lot of businesses are working with Chinese companies to make new medicines. This change is hurting the European pharmaceutical industry because money is moving away from Europe.
Ten years ago, only 4% of the drugs being developed around the world were made in China. Today, that number is almost one-third. This big change shows how fast China is moving forward and how it is affecting the decline of the European pharmaceutical industry.
This trend is backed up by a report from PitchBook:
“China’s biopharma advantage will likely last, even though there is more geopolitical tension, because of continued licensing, targeted fundraises, and different kinds of science.”
From being a world leader to falling behind
It’s especially surprising that the European pharmaceutical industry is doing so poorly now, given how well it has done in the past. In 1990, Europe did almost half of all research and development in the world for pharmaceuticals. Now, that number is only 26%, and the U.S. is in the lead with 55%.
This change shows how serious the decline in the European pharmaceutical industry is. Companies have been unhappy with Europe’s complicated system for years. There are different rules, prices, and ways to get things approved in different countries. This makes it harder for businesses to run smoothly.
Money is another problem. European biotech companies get a lot less money than U.S. biotech companies—sometimes five to ten times less. This lack of money is another major reason why the European pharmaceutical industry is going down.
Changes in investments and risks in the future
The decline of the pharmaceutical industry in Europe is already having an effect on business decisions. Companies are now deciding between markets with a lot of sales and markets with a lot of profit. For some drugs, this means putting off or even skipping launches in Europe.
Greg Graves brought up this problem:
He said, “For every company I’ve worked with, a lot of thought goes into [those options].”
Diederik Stadig also gave a warning:
He said, “For drugs that value is the answer, launches in Europe will be delayed.”
If these trends keep up, the decline of the European pharmaceutical industry could get worse, with more money going to the U.S. and China.
Demand for Quick Changes
Experts all agree that something needs to be done right away to stop the decline of the European pharmaceutical industry. The European Federation of Pharmaceutical Industries and Associations (EFPIA) wants more money to be spent, better rules, and faster access to medicines.
Nathalie Moll stressed how important it is to change:
“We need to spend more money and get rid of government clawbacks and taxes. These policies are important for keeping businesses in the EU and making it easier for people to get to them,” she said.
Europe only spends about 1% of its GDP on drugs right now. The U.S. spends 2% and China spends 1.8%. The decline of the European pharmaceutical industry will probably continue if things don’t get better.
The European pharmaceutical industry is at a crucial turning point in its decline.
The decline of the European pharmaceutical industry is a complicated problem that has to do with competition from other countries, changes in policy, and problems within the industry itself. Europe is losing its place as the world’s leader in pharmaceuticals because of U.S. policies and China’s rapid growth.
If major changes aren’t made, the decline of the European pharmaceutical industry could mean fewer new medicines, less investment, and less access to new medicines for patients.
The decline of the European pharmaceutical industry now depends on how quickly Europe can adapt and compete in a world that is changing.
1 Comment